R-chop

R-chop has been studied in 6 papers since 2021: 6 observational studies in people; 2 in the past year. The newest paper, May 19, 2026: “A Modified Simplified Frailty Score Predicts Survival, Toxicity, and Treatment Selection in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study”.

Intervention

6 papers study it3 findingsUpdated

See all 6 papers on r-chop

At a glance

The findings reach people, from one lab or study. 2 independent labs in 1 country; 58 trials, none about aging, 12 with no results posted.

“For fit patients, full-dose R-CHOP (initial dosage >80%) was associated with better survival than attenuated R-CHOP ([R-miniCHOP]; 2-year OS: 86% vs 70%; P = .012), also in adjusted analyses.”
A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCLBlood advances2021doi:10.1182/bloodadvances.2021004777

1 of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 2 independent labs in 1 country
  • 1 finding against
  • 58 trials, none about aging, 12 with no results posted
  • Humans6

What did studies of r-chop find?

2

Studies of r-chop measured 2 outcomes: survival and complete response.

Survival

no changein humans1upin humans1

1 study
  1. R-chop was not clearly linked with survival in humans (unfit and frail patients with DLBCL).

    Humansunfit and frail patients with DLBCL

  2. R-chop is linked with better survival in humans (fit patients with DLBCL) (2-year OS: 86% vs 70%; P = .012).

    Humansfit patients with DLBCL

Complete response

downin humans1

1 study
  1. R-chop is linked with lower complete response in humans (mSFS-fit patients, versus fit R-CHOP patients) (88% lower odds; aOR 0.12, p = 0.003).

    HumansmSFS-fit patients, versus fit R-CHOP patientsdose-attenuated (R-mini-CHOP)

Has r-chop been tested in people?

0 of 58 about aging

Yes: 6 observational studies in people have been published, and 58 trials are registered.

In trials

All 17

Who is developing r-chop?

1 company: Beijing InnoCare Pharma Tech.

Companies
  • Beijing InnoCare Pharma TechPhase 3treatment na ve mantle cell lymphoma, diffuse large B-cell lymphoma

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 02 papers in 12 months